Study on Aspirin Use for Heart Attack Prevention in Diabetes Patients

Overview of Diabetes and Cardiovascular Risk

A recent study published in the New England Journal of Medicine investigated the safety and effectiveness of aspirin for heart attack prevention in patients with diabetes. With approximately 400 million individuals affected by diabetes globally, these patients face a two to three times higher risk of developing cardiovascular disease. This category includes conditions that impact the heart or blood vessels, such as coronary heart disease, which can lead to serious outcomes like heart attacks and strokes.

Aspirin’s Role in Heart Attack Prevention

Aspirin is known to inhibit blood clotting, a process where platelets aggregate to stop bleeding. While this is beneficial, excessive clot formation can obstruct arteries supplying blood to the heart, potentially resulting in a heart attack. Aspirin effectively diminishes this clumping action, making it a common intervention among patients with existing cardiovascular disease.

Previous Research Findings

Earlier studies indicated that aspirin usage could lower the risk of serious cardiovascular events by 12%. However, this benefit comes with a 50% increased risk of bleeding, which may negate the advantages for low-risk cardiovascular patients. Additionally, some research suggested that low-dose aspirin could decrease the incidence of cancer or cancer-related mortality by 15-20%, although these studies included a limited number of diabetic patients.

New Research on Aspirin for Diabetic Patients

To further explore aspirin’s effects, researchers in the UK conducted a randomized trial involving 15,480 adults with diabetes but no prior cardiovascular issues. Participants were assigned to receive either a daily dose of 100 mg of aspirin or a matching placebo.

Trial Results and Implications

The study’s findings revealed that, after an average follow-up of 7.4 years, participants taking aspirin experienced fewer serious cardiovascular problems compared to those receiving the placebo. However, there was a higher incidence of major bleeding events among the aspirin group. Notably, no significant differences were found in the occurrence of gastrointestinal or other cancers between the two groups.

Conclusion on Aspirin’s Benefits and Risks

The results indicate that while aspirin is effective in preventing serious cardiovascular issues in diabetes patients without a history of such problems, it also poses a risk for major bleeding. Nevertheless, the benefits associated with aspirin in heart attack prevention and the reduction of other serious cardiovascular complications are considered to outweigh the bleeding risks. Long-term follow-up studies are necessary to further evaluate the lasting effects and cancer incidence reliability.

References

Written by Lacey Hizartzidis, PhD.
Reference: Daily aspirin therapy: Understand the benefits and risks. Mayo Clinic website https://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/daily-aspirin-therapy/art-20046797. Accessed August 31st, 2018.
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. August 2018. doi:10.1056/NEJMoa1804988.